Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Hungary

Hungary Articles

Industry

BMI View: As BMI warned it would back in February, [1] the Hungarian government has announced new deeper cuts to its pharmaceutical budget for this year and next. Our markedly pessimistic... 2012-04-30


Industry

Funding for Hungary's predominantly publically funded healthcare system will remain under pressure in 2012 and 2013. While the National Healthcare Fund (OEP)'s annual budget has risen,... 2012-04-12


Industry

BMI View: with a few exceptions, the attractiveness of Central And Eastern European (CEE) pharmaceutical markets has remained relatively stable in our Q312 Risk/Reward Ratings (RRRs)... 2012-04-05


Industry

BMI View: Governments across Central Europe have been quick to introduce drug policy reforms that aim to reduce pharmaceutical expenditure and shift the financial burden on to patients... 2012-03-12


Industry

BMI View: The Central And Eastern European (CEE) countries included in Pharmaceutical Research and Manufacturers of America (PhRMA)'s Special 301 submission to the Office of the US... 2012-03-02


Industry

BMI View: Drugmakers operating in Hungary should be concerned by the latest comments from an important member of Hungary's Fidesz party that indicate the government may be preparing... 2012-02-29


Industry

BMI View: Governments across Central Europe have been quick to introduce drug policy reforms that aim to reduce pharmaceutical expenditure and shift the financial burden on to patients... 2011-11-02


Industry

BMI View: Central and Eastern Europe (CEE)'s attractiveness to drugmakers has improved. BMI's Pharmaceuticals and Healthcare Business Environment Ratings (BERs), which assess markets... 2011-10-12


Industry

BMI View: Small changes to Hungary's 2012 budget plan are moderately good news for drugmakers. However, longer-term savings targets have been maintained and the impact of legislated... 2011-10-11


Industry

BMI View: The biosimilar licencing deals signed between Gedeon Richter and Stada are mutually beneficial, lowering the risks and costs associated with drug development and adding to... 2011-08-31

11 to 20 of 105 results
<< | < | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | > | >>
Insight